Navigation Links
Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Date:7/16/2009

SAN FRANCISCO, July 16 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed a private placement of shares of its common stock and warrants to purchase additional common stock for aggregate gross proceeds of approximately $3.4 million. Riverbank Capital Inc., a FINRA member broker dealer acted as the exclusive placement agent for the transaction.

"We are extremely pleased to have the completed this financing," said Joshua Kazam, Chief Executive Officer, "which we believe will provide us with sufficient capital to complete our Phase 2 clinical study of CD-NP in acute heart failure patients with mild to moderate renal insufficiency."

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under such act and applicable state securities laws or an applicable exemption from those registration requirements. Nile has agreed to file a registration statement covering the resale of the shares issued in the private placement, including the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas o
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
2. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
7. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
8. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
11. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014  Having the right people at the ... accelerating business growth and achieving clinical and operational goals. ... Leadership Summit, July 20-22, 2014, in San ... executives and healthcare experts discussing how partnerships have positively ... President & Chief Executive Officer of Cape Regional Medical ...
(Date:7/23/2014)... DES MOINES, Iowa (PRWEB) July 23, 2014 ... will join the business as vice president of Agricultural ... from Mendel Biotechnology where he served most recently as ... brings extensive biotechnology and business leadership in the seed ... DuPont Pioneer,” said Paul E. Schickler , president ...
(Date:7/23/2014)... 23, 2014  GrowBLOX Sciences, Inc. (OTCQB: GBLX), a medical ... filing for two medical marijuana dispensary locations in ... to the Clark County, Nevada dispensary ... as previously announced.  GrowBLOX Sciences, CEO Craig ... new applications for dispensaries in the City of ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 OncLive® ... Cancer Center has joined its Strategic Alliance Partnership ... Alliance Partnership program, UNC Lineberger will have the ... raise awareness of its cutting-edge research initiatives, community-directed ... UNC Lineberger will work with OncLive to educate ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
... , SAN FRANCISCO, Dec. 1 Medizone International, ... tests involving its proprietary AsepticSure(TM) technology, it continues to ... very different spore forming bacteria, Claustridium difficile and Bacillis ... potent sporicidal technology. "The implications of a 6.7 log ...
... ... comprehensive training programs, including biomedical repair technologies. Their shared efforts will begin in 2010 ... ... the recent signing of a Memorandum of Understanding, Mercy Ships and MediSend International have ...
... Cambridge, Mass November 30, 2009 An ... Photonics, and ETH Zrich have demonstrated compact, multibeam, ... of the light spectrum (infrared). By contrast, typical ... well-defined wavelength. The innovative multibeam lasers have potential ...
Cached Biology Technology:Medizone International Takes Aim at the Bioterrorism Countermeasures Arena 2Mercy Ships and MediSend International Partner to Deliver Hope and Healing 2Mercy Ships and MediSend International Partner to Deliver Hope and Healing 3Scientists demonstrate multibeam, multi-functional lasers 2
(Date:7/23/2014)... New Rochelle, NY -- The potential for clinical ... for transplant-based therapeutic strategies has previously been hindered ... the development of tumors. The ability to use ... for the treatment of heart disease, specifically acute ... Stem Cells and Development , a peer-reviewed ...
(Date:7/23/2014)... BCC Research ( ... MARKETS AND TECHNOLOGIES FOR SENSORS , the global market ... to nearly $154.4 billion by 2020, with a five-year ... flow, and level sensors segment is moving at a ... ) , Sensors have become indispensable to ...
(Date:7/23/2014)... . , Animals ... which might be very different from ours. Some bird ... sunlight in the atmosphere to calibrate their orientation systems. ... in Seewiesen, Germany, and Queen,s University Belfast have discovered ... the greater mouse-eared bat, has the capability to orient ...
Breaking Biology News(10 mins):Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3Bats use the evening sky's polarization pattern for orientation 2
... has uncovered a protein that plays a vital role in ... in improving the production and quality of crops and biofuels. ... PNAS . The team included researchers from Dartmouth, ... Plant roots use their endodermis, or inner skin, as a ...
... Frederick will present new research at the 108th Annual ... and women,s beliefs about who should pay for dates ... expenses. The paper, Who Pays for Dates? Following versus ... than 17,000 participants; a quarter of whom also provided ...
... Vision licensee, Theresa Ayers , has added a second location ... Ronald Ayers , the husband-and-wife team assumed ownership last month ... Theresa Ayers has been with Pearle Vision, one of ... for more than three decades. She began her career working for ...
Cached Biology News:Research on which gender pays for dates shows change and resistance from convention 2Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 2Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 3Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 4Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 5
... of 2D polyacrylamide gel electrophoresis (2D-PAGE) with ... a core technology platform for proteomic analysis. ... complex samples limited only in the dynamic ... large proteins. Quantitative image based analysis of ...
...
... use in Refrigerated Vapor Trap Models RVT100, ... (UVS) Models UVS400, UVS400A and UVS800DDA., A ... for use for temperatures ranging from -105 ... thermal stability and does not evaporate. Far ...
... 10X Automation Buffer is a concentrated formulation ... autostainers employing capillary action technology, as well ... in collaboration with David Brigati M.D., Department ... OK. This buffer is recommended for all ...
Biology Products: